SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
[December 05, 2018]

BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)


CAMBRIDGE, Mass. and BEIJING, China, Dec. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on November 30, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 46,689 American Depositary Shares to 144 new employees under BeiGene’s Amended and Restated 2018 Inducement Equity Plan.

The Amended and Restated 2018 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by BeiGene or one of its subsidiaries as an inducement material to such individual's entering into employment with BeiGene or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ isting Rules.



The restricted share units will vest 25 percent on each anniversary of the grant, subject to the employees’ continued employment with BeiGene or one of its subsidiaries. The restricted share units are subject to the terms and conditions of BeiGene’s Amended and Restated 2018 Inducement Equity Plan and forms of award agreements covering the grants.

About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,700 employees in China, the United States, Australia and Switzerland, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i


Investor Contact         Media Contact
Craig West     Liza Heapes
+1 857-302-5189 +1 857-302-5663
ir@beigene.com   media@beigene.com

i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.


BEI_ONC_4C_FlatLogo_Horizontal.jpg


[ Back To TMCnet.com's Homepage ]







Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy